36287-37-3

Upstream product

• 2859-78-1 4-Bromoveratrole 
• 594-19-4 tert.-butyl lithium 
• 107-02-8 acrolein 
• 1835-04-7 ethyl 3,4-dimethoxyphenyl ketone 
• 91-16-7 1,2-dimethoxybenzene 
• 1835-05-8 2-bromo-1-(3,4-dimethoxyphenyl)propan-1-one 

Downstream Products

• 521-54-0 (±)-galbulin 
• 528-63-2 all-cis-3,4-dimethyl-2,5-bis(3,4-dimethoxyphenyl)tetrahydrofuran 
• 528-63-2 (2R*,3R*,4R*,5R*)-2,5-bis(3,4-dimethoxyphenyl)-3,4-dimethyltetrahydrofuran 
• 5701-82-6 2,3-bis[(3,4-dimethoxyphenyl)methyl]butane 
• 528-63-2 (2R*,3R*,4R*,5S*)-2,5-bis(3,4-dimethoxyphenyl)-3,4-dimethyltetrahydrofuran 
• 4676-33-9 3,4-dimethyl-2,5-bis(3,4-dimethoxyphenyl)furan 
• 528-63-2 galgravin 

Relevant academic research and scientific papers

Bioinspired total synthesis of tetrahydrofuran lignans by tandem nucleophilic addition/redox isomerization/oxidative coupling and cycloetherification reactions as key steps

A very short three-step approach to trans,trans,trans-2,5-diaryl-3,4-dimethyltetrahydrofuran lignans is reported. The carbon skeleton is assembled in a single step based on an unprecedented tandem reaction consisting of 1,2-addition of aryllithium reagents to α,β-unsaturated aldehydes, ruthenium-catalyzed redox isomerization of the resulting alkoxides to enolates and their dimerization triggered by single electron oxidation. The resulting 2,3-dialkyl-1,4-diketones form with moderate to good d/l-diastereoselectivity and are transformed to the target tetrahydrofuran lignans by reduction and diastereoselective cycloetherification.

2,5-diaryl tetrahydrothiophenes and analogs thereof as PAF-antagonists

Analogs of 2,5-Diaryl tetrahydrothiophenes which were substituted or unsubstituted on 3,4-positions were prepared. These compounds are found to be leukotriene inhibitors and potent and specific PAF (Platelet Activating Factor) antagonists. They are th